Dyslipidemia Clinical Trial
— VYCTORYOfficial title:
A Multicenter, Open-label, 6 Week Study to Evaluate the Efficacy and Safety of Algorithm Based Intensive Treatment With Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Patients.
NCT number | NCT01587235 |
Other study ID # | 0653A-406 |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | March 2013 |
Est. completion date | May 2014 |
Verified date | February 2022 |
Source | Organon and Co |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate and compare the effectiveness of MK-0653 (Vytorin) to current standard treatment with other statins for the treatment of dyslipidemia in moderate, moderately-high and high-risk participants.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 2014 |
Est. primary completion date | May 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 79 Years |
Eligibility | Inclusion Criteria: - Low-density lipoprotein cholesterol (LDL-C) =100 mg/dL - Either treatment naïve (no previous treatment with lipid-lowering medication) or if previously treated with lipid-lowering medication, must complete a wash-out 6 weeks prior to enrollment Exclusion Criteria: - LDL-C level = 190 mg/dL - Hypersensitivity or intolerance to Vytorin, ezetimibe or simvastatin - Taking other lipid lowering agent except statins. (i.e. fenofibrate, niacin, ezetimibe, etc) - Pregnant or breastfeeding, or expecting to conceive within the projected duration of the study - Currently participating in or has previously participated in a study within 30 days - Congestive heart failure defined by New York Heart Association (NYHA) Class III or IV within previous 6 months - Uncontrolled cardiac arrhythmias or recent significant electrocardiogram (ECG) changes - Unstable angina pectoris - Myocardial infarction, coronary artery bypass surgery, or angioplasty within previous 3 months - Unstable or severe peripheral artery disease within previous 3 months - Uncontrolled hypertension (treated or untreated) - Type 1 or Type 2 diabetes mellitus that is poorly controlled or recently diagnosed (within previous 3 months) - Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins - Serious cerebrovascular disorder (ischemic stroke or cerebral hemorrhage) within the previous 6 months - Received treatment with systemic corticosteroids, any cyclical hormones within previous 8 weeks |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Organon and Co |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants who Achieve Low-density Lipoprotein Cholesterol (LDL-C) goal (High-risk <100 mg/dL; Moderate-high and High risk <130 mg/dL) | Week 6 | ||
Secondary | Change in LDL-C level From Baseline | Baseline and Week 6 | ||
Secondary | Number of High-risk Participants who Achieve an LDL-C < 70 mg/dL | Week 6 | ||
Secondary | Change in Serum LDL From Baseline | Baseline and Week 6 | ||
Secondary | Change in Total Cholesterol From Baseline | Baseline and Week 6 | ||
Secondary | Change in High-density lipoprotein (HDL) From Baseline | Baseline and Week 6 | ||
Secondary | Change in Serum Triglycerides (TG) From Baseline | Baseline and Week 6 | ||
Secondary | Change in Serum Non-HDL From Baseline | Baseline and Week 6 | ||
Secondary | Change in LDL-C/HDL-C Ratio From Baseline | Baseline and Week 6 | ||
Secondary | Change in Apolipoprotein B (ApoB) From Baseline | Baseline and Week 6 | ||
Secondary | Number of Participants who Achieve non-HDL-C goal (High-risk <100 mg/dL; Moderate-high and High risk <160 mg/dL)) | Week 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
Recruiting |
NCT02837367 -
Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People
|
N/A | |
Active, not recruiting |
NCT02223793 -
Vascular Lifestyle-Intervention and Screening in Pharmacy
|
N/A | |
Active, not recruiting |
NCT02600338 -
Meta-analyses of the Effect of Legumes on Blood Pressure
|
N/A | |
Completed |
NCT02163044 -
The Hellenic Postprandial Lipemia Study (HPLS)
|
||
Recruiting |
NCT01972113 -
Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)
|
N/A | |
Recruiting |
NCT01705873 -
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
|
N/A | |
Completed |
NCT01764295 -
Clinical Study for Patients With Hypertension Associated With Dyslipidemia
|
Phase 3 | |
Completed |
NCT01990391 -
Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities
|
N/A | |
Completed |
NCT01531062 -
Effect of Nigella Sativa on Lipid Profiles in Elderly
|
Phase 2 | |
Terminated |
NCT01414166 -
Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)
|
Phase 3 | |
Recruiting |
NCT01670968 -
HIV Reverse Cholesterol Transport Study
|
||
Completed |
NCT00977288 -
A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)
|
Phase 2 | |
Completed |
NCT01285544 -
The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia
|
Phase 4 | |
Completed |
NCT00768274 -
Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00664287 -
Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)
|
Phase 3 | |
Completed |
NCT01483235 -
Reduced Cardiac Rehabilitation Program
|
N/A | |
Completed |
NCT00300430 -
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
|
Phase 3 | |
Completed |
NCT00309777 -
Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin
|
Phase 3 |